Optic IconOptic Logo
|
SearchCollectionsBenchmarks

MASCT-I

2 abstracts

Abstract
Updated results on multiple antigens stimulating cellular therapy (MASCT-I) in metastatic urothelial carcinoma: A randomized, open-label, phase I trial.
Org: HRYZ Biotech Co. Ltd.,
Abstract
Multiple antigen stimulating cellular therapy (MASCT)-I for metastatic urothelial carcinoma (mUC): A multicenter, phase I study (MASCT-I-1001).
Org: Sun Yat-sen University Cancer Center Gansu Hospital, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Center for Cancer Medicine, Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China,